<?xml version='1.0' encoding='utf-8'?>
<document id="29451681"><sentence text="Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates."><entity charOffset="65-74" id="DDI-PubMed.29451681.s1.e0" text="ritonavir" /></sentence><sentence text="Ritonavir is one of several ketoconazole alternatives used to evaluate strong CYP3A4 inhibition potential in clinical drug-drug interaction (DDI) studies"><entity charOffset="0-9" id="DDI-PubMed.29451681.s2.e0" text="Ritonavir" /><entity charOffset="28-40" id="DDI-PubMed.29451681.s2.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29451681.s2.e0" e2="DDI-PubMed.29451681.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29451681.s2.e0" e2="DDI-PubMed.29451681.s2.e1" /></sentence><sentence text=" In this study, four physiologically based pharmacokinetic (PBPK) models of ritonavir as an in vivo time-dependent inhibitor of CYP3A4 were created and verified for oral doses of 20, 50, 100 and 200 mg using the fraction absorbed (Fa ) and oral clearance (CLoral ) values reported in the literature, because transporter and CYP enzyme reaction phenotyping data were not available"><entity charOffset="76-85" id="DDI-PubMed.29451681.s3.e0" text="ritonavir" /></sentence><sentence text=" The models were used subsequently to predict and compare the magnitude of the AUC increase in nine reference DDI studies evaluating the effect of ritonavir at steady-state on midazolam (CYP3A4 substrate) exposure"><entity charOffset="147-156" id="DDI-PubMed.29451681.s4.e0" text="ritonavir" /><entity charOffset="176-185" id="DDI-PubMed.29451681.s4.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.29451681.s4.e0" e2="DDI-PubMed.29451681.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29451681.s4.e0" e2="DDI-PubMed.29451681.s4.e1" /></sentence><sentence text=" Midazolam AUC and Cmax ratios were predicted within 2-fold of the respective observations in seven studies" /><sentence text=" Simulations of the hepatic and gut CYP3A4 abundance after multiple oral dosing of ritonavir indicated that a 3-day treatment with ritonavir 100 mg twice daily is sufficient to reach maximal CYP3A4 inhibition and subsequent systemic exposure increase of a CYP3A4 substrate, resulting in the reliable estimation of fm,CYP3A4 "><entity charOffset="83-92" id="DDI-PubMed.29451681.s6.e0" text="ritonavir" /><entity charOffset="131-140" id="DDI-PubMed.29451681.s6.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.29451681.s6.e0" e2="DDI-PubMed.29451681.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29451681.s6.e0" e2="DDI-PubMed.29451681.s6.e1" /></sentence><sentence text=" The ritonavir model was submitted as part of the new drug application for Kisqali® (ribociclib) and accepted by health authorities"><entity charOffset="5-14" id="DDI-PubMed.29451681.s7.e0" text="ritonavir" /></sentence><sentence text="" /></document>